One possible mechanism by which CCL2 recruits BMDM to the TME could be the binding of circulating CCL2 molecules to glycosaminoglycans in gliomas to establish a concentration gradient that guides monocytes toward the site of inflammation. Here, CCL2 is linked to central nervous system cancer.